There is one clinical trial.

Clinical Trials

1 Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection

In December 2019, a pneumonia due to a novel coronavirus (2019-nCoV) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of 2019-nCoV infection has dramatically increased, with almost 20'000 cases and more than 400 reported deaths on January, 31st 2020. Little is known on the rate of human-to-human transmission of this new coronavirus 2019-nCoV. In France, subjects with contact considered to be at high or moderate risk of viral transmission with a laboratory-confirmed 2019-nCoV case are being isolated at their home for 14 days and followed up by Santé Publique France or the Agence Régionale de Santé. Whether such subjects become spreaders of the virus, nor is the proportion of viral spreader who will develop a symptomatic infection. In this study, the investigators aim to evaluate the virological and clinical outcomes of subjects following a contact at high/moderate risk of 2019-nCoV transmission. The study population is represented by all subjects who had a contact with laboratory-confirmed 2019-nCoV cases and whose contact was considered to be at high/moderate risk of 2019-nCoV transmission, as defined with precise criteria emitted by the Health Ministry and Santé Publique France. Procedures added by the research: Nasopharyngeal swabs for determination of the presence of 2019-nCoV detected by Polymerase Chain Reaction (PCR). Blood sampling for determination of the presence of 2019-nCoV type M immunoglobulins or type G immunoglobulins by microneutralisation technique.

NCT04259892 Coronavirus Biological: 2019-nCoV PCR

MeSH:Coronavirus Infections

No related HPO nodes (Using clinical trials)